Aims and Scope Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged. The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research. Rapid Publication The journal’s rapid publication timelines aim for a peer review decision within 2 weeks of submission. If an article is accepted it will be published online 3-4 weeks from acceptance. These rapid timelines are achieved through the combination of a dedicated in-house editorial team, who closely manage article workflow, and an extensive Editorial and Advisory Board who assist with rapid peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid and efficient communication of the latest research and reviews, allowing the advancement of clinical therapies. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning that authors will always have a personal point of contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. We also encourage pre-submission enquiries and are always happy to provide a confidential assessment of manuscripts. Enhanced Digital Features Advances in Therapy is able to publish a range of additional enhanced digital features designed to increase visibility, readership, and the educational value of the content. Every paper is accompanied by a bulleted summary slide, giving a time-efficient overview of the key points of the content to a wider readership. Articles also have the option to include various other types of enhanced digital features including, but not limited to, slide sets, videos and video abstracts, infographics, podcasts and animations. All enhanced digital features are open access and are peer reviewed to the same high standard as the article itself. They can either be submitted at the same time as the manuscript or can be submitted retrospectively, and there is no additional cost to publish these features. By having a choice of media not limited to text, figures and tables alone, readers may receive information more efficiently, whilst being reassured that the content has undergone the same rigorous peer review as the original article. Offering succinct multimedia formats can support time-pressed healthcare professionals in keeping on top of recently published research. For questions relating specifically to enhanced digital features, please contact adisdigitalfeatures@springer.com. Plain Language Summaries Articles published in Advances in Therapy can be accompanied by Plain Language Summaries to assist in understanding important medical advances. These summaries can help the content to reach a broader audience thus supporting the effective dissemination of research. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors' or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other time point during consideration in our journal. Once the preprint is published, it is the author's responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and URL link to the published version of the article on the journal website. Please see here for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case by case basis and should be sent to the journal editor. Copyright Advances in Therapy's open access articles are published under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Publication Fees Upon acceptance of your article for publication, you will be required to pay the mandatory Rapid Service Fee of $7100 / €6250. Additionally, Advances in Therapy offers an open access option for all articles submitted to the journal. If you choose open access publication you will be required to pay an additional fee of €2990/$3760 upon acceptance of your article. The journal will consider fee discounts for developing countries and this is decided on a case by case basis. Contact For more information about the journal, please contact adisrapidplus@springer.com.
Advances in Therapy
Description
Identifiers
ISSN | 0741-238X |
e-ISSN | 1865-8652 |
DOI | 10.1007/12325.1865-8652 |
Publisher
Springer Healthcare
Additional information
Data set: Springer
Articles
Advances in Therapy > 2019 > 36 > 12 > 3424-3434
Introduction Gender disparities in access to healthcare have been documented, including disparities in access to care for cardiovascular diseases (CVDs). Disparities in access to cardiologists could disadvantage some patients to the newer lipid-lowering proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) antibodies, as utilization management criteria for PCSK9is often require step therapy...
Advances in Therapy > 2019 > 36 > 12 > 3368-3380
Introduction Seventy-five percent of ovarian cancer would relapse within 18–28 months after platinum-base chemotherapy. Evidence suggests that maintenance chemotherapy is effective in prolonging remission. Recent target therapies such as poly(ADP-ribose) polymerase inhibitors (PARPis) and angiogenesis inhibitors (AIs) are known to ease burden and recurrence of ovarian cancer. There is limited data...
Advances in Therapy > 2019 > 36 > 12 > 3356-3367
Introduction The effect of N-acetylcysteine (NAC) treatment for patients with chronic bronchitis (CB) is controversial. To better understand the role of NAC in CB treatment, we performed a meta-analysis to provide a more accurate estimation of the importance of NAC treatment. Methods PubMed, Embase, and CNKI were systematically searched. The pooled relative risk (RR) and 95% confidence intervals...